Advances in amyotrophic lateral sclerosis(ALS)research:Research in ALS has gained unprecedented momentum in recent years fueled by important conceptual developments,establishment of international consortia,breakthroug...Advances in amyotrophic lateral sclerosis(ALS)research:Research in ALS has gained unprecedented momentum in recent years fueled by important conceptual developments,establishment of international consortia,breakthrough genetic discoveries and relentless technological advances.The first genotypespecific pharmaceutical trials signal the paradigm shift from the notion of‘one-drug-for-all’to precision,individualized therapies.The once arcane presymptomatic phase of the disease is gradually unraveled by seminal studies of asymptomatic mutation carriers(Geevasinga et al.,2015;Querin et al.,2019).展开更多
基金supported by the Spastic Paraplegia Foundation,Inc.(SPF),the Health Research Board(HRB EIA-2017-019)the EU Joint Programme–Neurodegenerative Disease Research(JPND)+4 种基金the Andrew Lydon scholarship,the Irish Institute of Clinical Neuroscience(IICN),and the Iris O’Brien FoundationPB is the patron of the Irish Motor Neuron Disease Association(IMNDA)FC is supported by the EU-IKY Scholarship Program(European Social Fund-ESF)the Greek“Reinforcement of Postdoctoral Researchers”grant(5033021)of the“Human Resources Development ProgramEducation and Lifelong Learning”of the National Strategic Reference Framework(NSRF 2014-2020).
文摘Advances in amyotrophic lateral sclerosis(ALS)research:Research in ALS has gained unprecedented momentum in recent years fueled by important conceptual developments,establishment of international consortia,breakthrough genetic discoveries and relentless technological advances.The first genotypespecific pharmaceutical trials signal the paradigm shift from the notion of‘one-drug-for-all’to precision,individualized therapies.The once arcane presymptomatic phase of the disease is gradually unraveled by seminal studies of asymptomatic mutation carriers(Geevasinga et al.,2015;Querin et al.,2019).
